Veltassa
Drug
Relypsa, Inc.
Total Payments
$13.5M
Transactions
120,106
Doctors
19,326
Companies
5
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $309,439 | 6,262 | 2,739 |
| 2023 | $423,364 | 12,114 | 4,188 |
| 2022 | $562,609 | 12,370 | 4,093 |
| 2021 | $2.3M | 16,406 | 5,261 |
| 2020 | $2.5M | 10,030 | 3,390 |
| 2019 | $2.4M | 18,933 | 5,559 |
| 2018 | $2.6M | 20,359 | 6,978 |
| 2017 | $2.5M | 23,632 | 8,107 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.5M | 2,737 | 33.0% |
| Unspecified | $2.7M | 2,021 | 20.3% |
| Food and Beverage | $2.6M | 110,111 | 19.3% |
| Consulting Fee | $2.2M | 580 | 16.0% |
| Travel and Lodging | $1.2M | 4,366 | 9.0% |
| Grant | $183,651 | 9 | 1.4% |
| Space rental or facility fees (teaching hospital only) | $131,911 | 60 | 1.0% |
| Education | $5,333 | 222 | 0.0% |
Payments by Type
General
$10.8M
118,085 transactions
Research
$2.7M
2,021 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| DIAMOND PAT-CR-302 | Vifor (International) Ltd. | $1.5M | 26 |
| PAT-CR-302 | Vifor (International) Ltd. | $1.1M | 3 |
| Emerald | RELYPSA, INC. | $43,605 | 0 |
| Association of Potassium Levels with Mortality in Hospitalized Patients | RELYPSA, INC. | $39,474 | 0 |
| Emerald | Vifor Pharma, Inc. | $19,253 | 0 |
| Emerald | Relypsa, Inc. | $1,000 | 0 |
| PLATINUM | Vifor Pharma, Inc. | $495.00 | 1 |
| Symphony Health | Vifor Pharma, Inc. | $475.00 | 1 |
Ad
Manufacturing Companies
- Relypsa, Inc. $8.1M
- Vifor (International) Ltd. $3.1M
- Vifor Pharma, Inc. $2.2M
- Vifor Fresenius Medical Care Renal Pharma Ltd. $100,417
- RELYPSA, INC. $83,078
Product Information
- Type Drug
- Total Payments $13.5M
- Total Doctors 19,326
- Transactions 120,106
About Veltassa
Veltassa is a drug associated with $13.5M in payments to 19,326 healthcare providers, recorded across 120,106 transactions in the CMS Open Payments database. The primary manufacturer is Relypsa, Inc..
Payment data is available from 2017 to 2024. In 2024, $309,439 was paid across 6,262 transactions to 2,739 doctors.
The most common payment nature for Veltassa is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($4.5M, 33.0% of total).
Veltassa is associated with 8 research studies, including "DIAMOND PAT-CR-302" ($1.5M).